RGI-Ab02

N/A

Report date: 2024/10/28 11:59:20

Base Information

Drug NameRGI-Ab02
Drug Alias NameRGI-Ab02RGI-AB-02
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionCheckpoint kinase inhibitorsNatural killer cells stimulantsAntibody-dependent cell-mediated cytotoxicity (ADCC) effects +[4] 
TargetsCheckpoint kinase
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesREGiMMUNE Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesREGiMMUNE Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A